Market situation of anti osteoporosis drugs in China

It is understood that China has become the country with the largest number of osteoporosis patients in the world, whose severity is second only to cardiovascular disease The national large-scale epidemiological survey also shows that the total prevalence rate of osteoporosis in China is 12.4%, and the prevalence rate of the elderly is more than half, of which the incidence of fracture is close to 33% Some experts predict that by 2020, the number of osteoporosis and low bone mass patients in China will increase to 280 million In the future, anti osteoporosis drugs are promising At present, the prevention and treatment of osteoporosis drugs are diphosphonate, calcium preparations, estrogen, androgen, vitamin D, calcitonin and hormone replacement therapy [overall impression] according to the data of global best-selling drugs, in 2012, the top five categories of osteoporosis drugs in the world were: zoledronic acid sales of US $1.89 billion, tripatide of US $1.35 billion, dinomb of US $1.26 billion, raloxifene of US $1.01 billion and alendronate of US $860 million The top four products are the heavyweight products with annual sales of more than US $1 billion, among which, dinomb increased by 56.0% over the same period, and tripatide increased by 29.0% over the same period, with a gratifying growth rate In recent years, the international market for osteoporosis drugs is not strong enough The sales volume increased from $7.9 billion in 2005 to $9.55 billion in 2007, and fell back to $7.98 billion in 2012 The global osteoporosis drug market is mainly divided by Novartis, Amgen, Lilly and other giants Among them, the sales volume of zoledronic acid of Novartis is US $1.88 billion; the sales volume of dinozumab of Amgen is US $1.26 billion; the sales volume of tripatide of Lilly is US $1.15 billion, and the sales volume of raloxifene is US $1.01 billion; the sales volume of lisedronic acid of Sanofi is US $690 million; the sales volume of alendronate of MSD is US $680 million The giants have high brand awareness in their respective segments It is worth noting that the new biological drug of Anjin company, dinozumab (trade name: xgeva), has been increasing rapidly since it came into the market in 2011 Now, it has ranked the second place in the world in terms of osteoporosis, and may become the best-selling drug in the future According to the data of 22 sample hospitals in China, the market scale of osteoporosis drugs in China increased from 230 million yuan in 2005 to 1.03 billion yuan in 2013, with a growth rate of 7.2% in 2013; the compound growth rate of drug purchase amount from 2005 to 2013 was 20.6%, far higher than the average value of drug industry In addition, the proportion of the amount of osteoporosis drugs in the total amount of drugs has increased year by year, and the overall market has increased nearly 5 times in 8 years Most of the market shares are contributed by zoledronic acid, salmon calcitonin, alendronate sodium, alfacalcitol and ibandronate sodium At present, there are 15 major osteoporosis drugs on the market in China In 2013, the top five products in terms of sales volume are zoledronic acid 400 million yuan, salmon calcitonin 170 million yuan, alendronate 120 million yuan, alfacalcohol 110 million yuan and ibandronate 68.81 million yuan The top five products account for 85% of the total market share, and the other 10 products share the remaining 15% share In 2013, the top 5 enterprises in the domestic market for the amount of osteoporosis drugs were: Novartis' product drug amount was 370 million yuan, MSD drug factory was 110 million yuan, Kunming becknorton was 57.14 million yuan, Zhengda Tianqing was 50.32 million yuan, Shenzhen Haiwang was 43.31 million yuan, accounting for 36.0%, 10.6%, 6.0%, 4.9% and 4.2% respectively Among them, Novartis zoledronic acid accounts for one third of the domestic market, with an increase of 18.4% compared with the same period in 2013 [key varieties] zoledronic acid increased a little According to the data of sample hospitals, the growth of zoledronic acid was relatively stable from 2005 to 2010, and it was in a high-speed growth period from 2011 to 2013 From 2005 to 2013, the annual compound growth rate of zoledronic acid was 56.0%, and the drug amount increased from 11.02 million yuan to 400 million yuan In 2011 and 2012, the growth rate was 59.1% and 45.9% respectively, while in 2013, the growth rate slowed down to 15.0% In the domestic sample hospital market, there are 11 manufacturers involved in zoledronic acid, among which, the amount of imported brand drugs is 280 million yuan, and the amount of domestic brand drugs is 120 million yuan, accounting for 70.7% and 29.3% respectively The sales volume of Novartis products is 280 million yuan, accounting for 70.7%; that of Jiangsu Zhengda Tianqing Pharmaceutical Co., Ltd is 44.72 million yuan, accounting for 11.1%; that of Jiangsu Hengrui Pharmaceutical Co., Ltd is 31.34 million yuan, accounting for 8.0%; and that of other enterprises is 10.2% Novartis' zoledronic acid "Zetai" for injection and zoledronic acid injection "miguda" have outstanding performance and occupy a dominant position in the market With the influx of more and more domestic enterprises, the market competition will be more intense The growth of salmon calcitonin slowed down in 1994, and Novartis salmon calcitonin entered the Chinese market, with the trade name of "secret interest" Since then, the salmon calcitonin of Italy's Masha pharmaceutical factory has been approved to be listed under the trade name "cork" The main formulations on the market are injection and nasal spray Domestic salmon calcitonin injection was first developed by Hebei United Pharmaceutical Co., Ltd in 1997, with the trade name of "bangruide" In recent years, the products of more than 10 domestic enterprises have been approved for listing According to the data of 22 sample hospitals in China, from 2005 to 2011, the product has been in a rapid growth trend; from 2012 to 2013, the growth rate slowed down From 2005 to 2013, the annual compound growth rate of salmon calcitonin was 11.4%, lower than the average value of the pharmaceutical industry; the amount of drug use increased from 72.8 million yuan in 2005 to 170 million yuan in 2013 From 2007 to 2010, the growth rate is more than 20%, which is relatively fast, but in 2012 and 2013, it shows a downward trend At present, there are 13 enterprises involved in salmon calcitonin in the sample hospital market, including 3 import enterprises and 10 local enterprises The product sales of Novartis is 96.62 million yuan, accounting for 56.0%; the product sales of Beijing Shiqiao bio Pharmaceutical Co., Ltd is 40.06 million yuan, accounting for 23.2%; the product sales of Asahi Chemical Industry Co., Ltd is 19.41 million yuan, accounting for 11.3%; the product sales of Shandong LVYE Pharmaceutical Co., Ltd is 10.04 million yuan, accounting for 5.8%; the other nine enterprises account for 3.6% Alendronate sodium belongs to the third generation bisphosphonates The product is suitable for the treatment of osteoporosis and osteoarthritis, and then approved as a prescription drug for the prevention of osteoporosis In 1996, China authorized the administrative protection of alendronate sodium tablets, and in 1998 approved the product "fushanmei" of Hangzhou mosadong company to enter the Chinese market According to the data of 22 sample hospitals in China, from 2005 to 2013, the drug use amount of the product has maintained a high-speed growth trend, with 27.32 million yuan in 2005 and 120 million yuan in 2011, and has remained between 120 million and 130 million yuan since then From 2005 to 2013, the annual compound growth rate of alendronate sodium was 20.5%, higher than the average value of the pharmaceutical industry Alendronate rose at a high speed for six consecutive years and declined slightly in 2013 In the sample hospital market, there are 13 enterprises involved in the production of alendronate, including 1 import enterprise and 12 domestic enterprises The sales volume of alendronate sodium of moshadong Pharmaceutical Co., Ltd is 110 million yuan, accounting for 90.0%; the drug consumption amount of Ouyi Pharmaceutical Co., Ltd of Shijiazhuang Pharmaceutical Group is 8.38 million yuan, accounting for 6.9%; the drug consumption amount of Beijing Wansheng Pharmaceutical Co., Ltd is 1.11 million yuan, accounting for 1.0% Alendronate market is basically monopolized by the original research drug "fushanmei" It is worth noting that in recent years, MSD Pharmaceutical Co., Ltd has listed a new product, compound alendronate sodium and vitamin D3 tablets, with a sales volume of 3.85 million yuan in 2012 and 20.37 million yuan in 2013, with a rapid growth rate.